Bausch & Lomb's private-equity owners are leaning toward launching an initial public offering of shares in the eye-health company after possible buyers of the business balked at the asking price of at least $10 billion, according to people familiar with the matter.
Bausch & Lomb owners shift focus to IPO
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.